James Vredenburgh, MD
Adjunct Assistant ProfessorAbout
Research
Publications
2024
Clinical utility of upfront liquid biopsy in non-small cell lung cancer in the community setting.
Doro L, Ozcan G, Vredenburgh J, Collier E. Clinical utility of upfront liquid biopsy in non-small cell lung cancer in the community setting. Journal Of Clinical Oncology 2024, 20: 316-316. DOI: 10.1200/op.2024.20.10_suppl.316.Peer-Reviewed Original ResearchNon-small cell lung cancerNon-small cell lung cancer patientsCell lung cancerLiquid biopsyAdvanced non-small cell lung cancerLung cancerDiagnosis of advanced non-small cell lung cancerDiagnosed NSCLCNext generation sequencingMolecular profilingClinical utilityLiquid biopsy resultsComprehensive molecular profilingTarget genetic abnormalitiesKRAS G12C mutationProportion of patientsProgression of eGFRPartial responsePlasma genotypingBiopsy resultsBRCA carriersTreatment failureOncoKB databaseSystemic treatmentActionable mutations
2023
Bevacizumab Alone and in Combination With Irinotecan in Recurrent Glioblastoma
Friedman H, Prados M, Wen P, Mikkelsen T, Schiff D, Abrey L, Yung W, Paleologos N, Nicholas M, Jensen R, Vredenburgh J, Huang J, Zheng M, Cloughesy T. Bevacizumab Alone and in Combination With Irinotecan in Recurrent Glioblastoma. Journal Of Clinical Oncology 2023, 41: 4945-4952. PMID: 37935104, DOI: 10.1200/jco.22.02772.Peer-Reviewed Original ResearchBevacizumab alone groupObjective response rateIrinotecan groupRecurrent glioblastomaResponse rateMedian overall survival timeProgression-free survival ratesEnd pointEfficacy of bevacizumabIndependent radiology reviewPrimary end pointSecondary end pointsProgression-free survivalOverall survival timeExperienced gradeNoncomparative trialsOverall survivalPatients patientsAdverse eventsRadiology reviewIntracranial hemorrhageBevacizumabSurvival timePatientsIrinotecan
1994
Clostridium septicum abscess in hepatic metastases: successful medical management.
Thel M, Ciaccia D, Vredenburgh J, Peters W, Corey G. Clostridium septicum abscess in hepatic metastases: successful medical management. Bone Marrow Transplantation 1994, 13: 495-6. PMID: 7517261.Peer-Reviewed Original ResearchMeSH KeywordsAdultAntineoplastic Combined Chemotherapy ProtocolsBone Marrow TransplantationBreast NeoplasmsCarmustineCeftazidimeCisplatinClindamycinClostridium InfectionsCombined Modality TherapyCyclophosphamideDoxorubicinDrug Therapy, CombinationEtoposideFemaleFluorouracilGasesGranulocyte Colony-Stimulating FactorHumansImipenemImmunocompromised HostLiver AbscessLiver NeoplasmsMethotrexateNeutropeniaSepsisConceptsHepatic metastasesMetastatic breast cancer treated with high-dose chemotherapyClostridium septicum bacteremiaHigh-dose chemotherapyBone marrow transplantationMarrow transplantationStandard therapySurgical debridementColonic malignancyMedical managementBacteremiaMetastasisExcess mortalityAntibioticsNeutropeniaChemotherapyAbscessMalignancyDebridementTransplantationTherapyPathophysiologyPatientsInfectionGangrene
Clinical Trials
Current Trials
Phase 2 Study of Pembrolizumab and Brentuximab Vedotin in Subjects With Relapsed/Refractory CD30 Positive T-cell Lymphoma
HIC ID2000029793RoleSub InvestigatorPrimary Completion Date04/30/2028Recruiting ParticipantsA Phase II/III Trial of Chemotherapy + Cetuximab vs Chemotherapy + Bevacizumab vs Atezolizumab + Bevacizumab Following Progression on Immune Checkpoint Inhibition in Recurrent/Metastatic Head and Neck Cancers
HIC ID2000032270RoleSub InvestigatorPrimary Completion Date12/15/2027Recruiting ParticipantsRandomized Phase III Study of Combination Osimertinib (AZD9291) and Bevacizumab Versus Osimertinib (AZD9291) Alone as First-Line Treatment for Patients With Metastatic EGFR-Mutant Non-Small Cell Lung Cancer (NSCLC)
HIC ID2000032879RoleSub InvestigatorPrimary Completion Date12/31/2026Recruiting ParticipantsAn Open-Label Phase II Trial to Evaluate the Efficacy and Safety of Neoadjuvant Doxorubicin Plus Cyclophosphamide Followed by Weekly Paclitaxel Plus Trastuzumab and Pertuzumab in Early Stage HER2-Negative Breast Cancer Patients Selected With a Test Measuring Live Cell HER2 Signaling Transduction (FACT 1)
HIC ID2000025449RoleSub InvestigatorPrimary Completion Date10/30/2023Recruiting ParticipantsA Randomized, Phase IIB, Multicenter, Trial of Oral Azacytidine Plus Romidepsin Versus Investigator's Choice in Patients With Relapse or Refractory Peripheral T-cell Lymphoma (PTCL)
HIC ID2000030190RoleSub InvestigatorPrimary Completion Date06/02/2026Recruiting Participants
News
News
- June 02, 2021
Yale Cancer Center and Smilow Cancer Hospital physicians recognized as Connecticut Magazine 'Best Doctors'
- June 04, 2020
Yale Cancer Center and Smilow Cancer Hospital physicians recognized as CT Magazine Best Doctors
- June 03, 2019
Yale Cancer Center and Smilow Cancer Hospital physicians recognized as CT Magazine 'Best Doctors'
- April 13, 2018
Connecticut Magazine recognizes Yale Cancer Center and Smilow Cancer Hospital physicians as 'Best Doctors'